Akebia Therapeutics (AKBA) News Today

Acadian Asset Management LLC cut its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 23.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,063,383 shares of the bio

HC Wainwright restated a "buy" rating and set a $7.50 price target on shares of Akebia Therapeutics in a research note on Friday.

Assenagon Asset Management S.A. cut its holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 73.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 211,647 shares of the biopharmaceutical company's stock after selling 578,836 shares during the

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a note issued to investors on Monday, August 12th. HC Wainwright analyst E. Arce expects that the biopharmaceut

Vanguard Group Inc. lifted its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 8.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,225,972 shares of the biopharm

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. The business had revenue of $43.65 million during the quarter, compared to the consensus estimate of $45.61 million. During the same period last year, the business posted ($0.06) earnings per share.

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 18,660,000 shares, a growth of 42.3% from the June 30th total of 13,110,000 shares. Based on an average daily trading volume, of 3,200,000 shares, the short-interest ratio is presently 5.8 days.

Acadian Asset Management LLC trimmed its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 23.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,309,755 shares of the biop

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 13,110,000 shares, an increase of 6.6% from the June 15th total of 12,300,000 shares. Based on an average daily volume of 3,290,000 shares, the short-interest ratio is currently 4.0 days.

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 12,300,000 shares, a drop of 6.5% from the May 31st total of 13,160,000 shares. Based on an average daily volume of 4,550,000 shares, the short-interest ratio is presently 2.7 days.

Akebia Therapeutics (NASDAQ:AKBA) Stock Price Passes Below Two Hundred Day Moving Average of $1.40

Akebia Therapeutics (NASDAQ:AKBA) Share Price Crosses Below Two Hundred Day Moving Average of $1.39

Victory Capital Management Inc. trimmed its position in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 97.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,519 shares of the biopharmaceutical company's sto

Assenagon Asset Management S.A. acquired a new stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 790,483 shares of the biopharmaceutical company's stock, valued

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). The business had revenue of $32.61 million during the quarter, compared to the consensus estimate of $41.13 million. During the same quarter last year, the company earned ($0.14) EPS.

StockNews.com downgraded Akebia Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.